Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with or without platinum-based chemotherapy in untreated advanced or metastatic urothelial carcinoma
NL-OMON45493Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Roche. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON45493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45493.